Cargando…

Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma

Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherapy are lacking. Cuproptosis is a newly discovered mode of cell death related to tumorigenesis. Exploring the relationship between the mode of cuproptosis and the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Da, Yang, Fan, Zhang, Tongtong, Mao, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885583/
https://www.ncbi.nlm.nih.gov/pubmed/36717900
http://dx.doi.org/10.1186/s12967-023-03891-4
_version_ 1784879958535962624
author Liu, Da
Yang, Fan
Zhang, Tongtong
Mao, Rui
author_facet Liu, Da
Yang, Fan
Zhang, Tongtong
Mao, Rui
author_sort Liu, Da
collection PubMed
description Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherapy are lacking. Cuproptosis is a newly discovered mode of cell death related to tumorigenesis. Exploring the relationship between the mode of cuproptosis and the effect of immunotherapy on CM could better guide clinical management. We clustered all patients with CM in the Cancer Genome Atlas (TCGA) database based on cuproptosis-related genes (CRGs). Prognosis, immunotherapeutic effect, tumor microenvironment score, expression of CD274, CTLA4, and PDCD1, and abundance of CD8 + T infiltration in group A were higher than in group B. Using a combination of LASSO and COX regression analysis, we identified 10 molecules significant to prognosis from differentially expressed genes between the two groups and constructed a cuproptosis-related scoring system (CRSS). Compared with the American Joint Committee on Cancer (AJCC) staging system, CRSS more accurately stratified CM patient risk and guided immunotherapy. CRSS successfully stratified risk and predicted the effect of immunotherapy in 869 patients with eight CM immunotherapy datasets and multiple other tumor immunotherapy cohorts. The nomogram model, which combined AJCC stage and CRSS, greatly improved the ability and accuracy of prognosis prediction. In general, our cuproptosis-related scoring system and nomogram model accurately stratified risk in CM patients and effectively predicted prognosis and the effect of immunotherapy in CM patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03891-4.
format Online
Article
Text
id pubmed-9885583
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98855832023-01-31 Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma Liu, Da Yang, Fan Zhang, Tongtong Mao, Rui J Transl Med Research Immunotherapy is a vital treatment for patients with cutaneous melanoma (CM), but effective predictors to guide clinical immunotherapy are lacking. Cuproptosis is a newly discovered mode of cell death related to tumorigenesis. Exploring the relationship between the mode of cuproptosis and the effect of immunotherapy on CM could better guide clinical management. We clustered all patients with CM in the Cancer Genome Atlas (TCGA) database based on cuproptosis-related genes (CRGs). Prognosis, immunotherapeutic effect, tumor microenvironment score, expression of CD274, CTLA4, and PDCD1, and abundance of CD8 + T infiltration in group A were higher than in group B. Using a combination of LASSO and COX regression analysis, we identified 10 molecules significant to prognosis from differentially expressed genes between the two groups and constructed a cuproptosis-related scoring system (CRSS). Compared with the American Joint Committee on Cancer (AJCC) staging system, CRSS more accurately stratified CM patient risk and guided immunotherapy. CRSS successfully stratified risk and predicted the effect of immunotherapy in 869 patients with eight CM immunotherapy datasets and multiple other tumor immunotherapy cohorts. The nomogram model, which combined AJCC stage and CRSS, greatly improved the ability and accuracy of prognosis prediction. In general, our cuproptosis-related scoring system and nomogram model accurately stratified risk in CM patients and effectively predicted prognosis and the effect of immunotherapy in CM patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03891-4. BioMed Central 2023-01-30 /pmc/articles/PMC9885583/ /pubmed/36717900 http://dx.doi.org/10.1186/s12967-023-03891-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Da
Yang, Fan
Zhang, Tongtong
Mao, Rui
Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
title Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
title_full Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
title_fullStr Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
title_full_unstemmed Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
title_short Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
title_sort leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885583/
https://www.ncbi.nlm.nih.gov/pubmed/36717900
http://dx.doi.org/10.1186/s12967-023-03891-4
work_keys_str_mv AT liuda leveragingacuproptosisbasedsignaturetopredicttheprognosisanddrugsensitivityofcutaneousmelanoma
AT yangfan leveragingacuproptosisbasedsignaturetopredicttheprognosisanddrugsensitivityofcutaneousmelanoma
AT zhangtongtong leveragingacuproptosisbasedsignaturetopredicttheprognosisanddrugsensitivityofcutaneousmelanoma
AT maorui leveragingacuproptosisbasedsignaturetopredicttheprognosisanddrugsensitivityofcutaneousmelanoma